Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...

Former NBA player Michael Carter-Williams is hoping to get a WNBA franchise in Boston whether it's through expansion a ...

Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

According to Benzinga Pro, Carlyle Group's peer group average for short interest as a percentage of float is 3.15%, which means the company has more short interest than most of its peers. Did you know ...

Record revenues from management fees and a brighter outlook for M&A in the year ahead helped private equity's Big Four close 2024 on a high note.

Korea Investment & Securities Co. will step up its asset management business by launching innovative global investment ...